Last reviewed · How we verify
Gadodiamide Injection
Gadodiamide is a gadolinium-based contrast agent that enhances magnetic resonance imaging by shortening the T1 relaxation time of water protons in tissues.
Gadodiamide is a gadolinium-based contrast agent that enhances magnetic resonance imaging by shortening the T1 relaxation time of water protons in tissues. Used for Contrast enhancement for magnetic resonance imaging of the central nervous system, Contrast enhancement for magnetic resonance imaging of the body.
At a glance
| Generic name | Gadodiamide Injection |
|---|---|
| Also known as | Omniscan |
| Sponsor | GE Healthcare |
| Drug class | Gadolinium-based contrast agent |
| Target | Water protons (T1 relaxation enhancement) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | Phase 3 |
Mechanism of action
Gadodiamide is a paramagnetic chelate complex containing gadolinium that distributes in extracellular fluid and accumulates in areas of blood-brain barrier disruption or abnormal vascularity. By altering the magnetic properties of nearby water molecules, it increases signal intensity in T1-weighted MRI images, allowing better visualization of tissue pathology, vascular structures, and lesions.
Approved indications
- Contrast enhancement for magnetic resonance imaging of the central nervous system
- Contrast enhancement for magnetic resonance imaging of the body
Common side effects
- Headache
- Nausea
- Dizziness
- Injection site reactions
- Gadolinium retention (systemic)
Key clinical trials
- Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging (PHASE4)
- A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-iliac Arteries While Using Gadodiamide (PHASE3)
- A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide (PHASE3)
- Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI) (PHASE4)
- A Study of Gadodiamide Injection in Myocardial Perfusion Magnetic Resonance Imaging (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadodiamide Injection CI brief — competitive landscape report
- Gadodiamide Injection updates RSS · CI watch RSS
- GE Healthcare portfolio CI